| Synonyms | Haldol |
| SPECIMEN REQUIREMENTS | |
| Container Type | Red top tube (plain) |
| Supply Item Number |  1372 |
| Specimen Type | Serum |
| Preferred Volume | 0.25 mL |
| Emergency Minimum Volume | 0.1 mL |
| Patient Prep | Timing of specimen collection: Pre-dose (trough) draw - At steady state concentration. |
| Specimen Processing | Separate serum or plasma from cells within 2 hours of collection and transfer to a standard PAML aliquot tube. |
| Store and Transport | Refrigerated |
| Stability | Refrigerated 2 weeks Frozen (-20 °C) 1 month |
| Unacceptable Condition | DO NOT use gel separator tubes (Corvac®, SST or equivalent) for the collection of blood samples for this test. |
| Alternate Specimens | Lavender top tube (EDTA) |
| Limitations | Avoid repeat freeze/thaw cycles |
| CPT Codes | 80173 |
| Interface Order Code | 80713 |
| Billing Code | HALP |
| Test Schedule | Mon, Wed, Fri |
| Turnaround Time | 1-3 days |
| Method | Tandem Mass Spectrometry |
| Reference Ranges | | Title | Descriptor | Ranges | Units | | Haloperidol | Therapeutic Range | 1-10 | ng/mL | | Toxic | > 10 |
|
| Compliance Remarks | This test was developed and its performance characteristics determined by PAML. The U.S. Food and Drug Administration (FDA) has not approved or cleared this test. However, FDA approval or clearance is currently not required for clinical use of this test. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. PAML is authorized under Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity testing. |
| Notes | Adverse effects may include drowsiness, blurred vision, tardive dyskinesia, tachycardia, nausea and vomiting. |
1372